| Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ... Cell stem cell 21 (3), 374-382. e4, 2017 | 713 | 2017 |
| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 476 | 2020 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 391 | 2021 |
| Acute promyelocytic leukemia: where did we start, where are we now, and the future CC Coombs, M Tavakkoli, MS Tallman Blood cancer journal 5 (4), e304-e304, 2015 | 317 | 2015 |
| Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors RN Ptashkin, DL Mandelker, CC Coombs, K Bolton, Z Yelskaya, ... JAMA oncology 4 (11), 1589-1593, 2018 | 162 | 2018 |
| Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors E Wang, X Mi, MC Thompson, S Montoya, RQ Notti, J Afaghani, ... New England Journal of Medicine 386 (8), 735-743, 2022 | 156 | 2022 |
| Molecular therapy for acute myeloid leukaemia CC Coombs, MS Tallman, RL Levine Nature reviews Clinical oncology 13 (5), 305-318, 2016 | 132 | 2016 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 121 | 2021 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 115 | 2020 |
| Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays CC Coombs, NK Gillis, X Tan, JS Berg, M Ball, ME Balasis, ... Clinical Cancer Research 24 (23), 5918-5924, 2018 | 100 | 2018 |
| Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia … DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Blood 134, 673, 2019 | 97 | 2019 |
| Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents M Duchmann, FF Yalniz, A Sanna, D Sallman, CC Coombs, A Renneville, ... EBioMedicine 31, 174-181, 2018 | 88 | 2018 |
| Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... New England Journal of Medicine 389 (1), 33-44, 2023 | 86 | 2023 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 80 | 2019 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood advances 4 (16), 3977-3989, 2020 | 75 | 2020 |
| Managing clonal hematopoiesis in patients with solid tumors KL Bolton, NK Gillis, CC Coombs, K Takahashi, A Zehir, R Bejar, ... Journal of Clinical Oncology 37 (1), 7, 2019 | 74 | 2019 |
| Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies G Falchook, S Rosen, P LoRusso, J Watts, S Gupta, CC Coombs, ... Clinical Cancer Research 26 (6), 1247-1257, 2020 | 69 | 2020 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 60 | 2021 |
| Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed (≥ 65 years … I Gojo, RK Stuart, J Webster, A Blackford, JC Varela, J Morrow, AE DeZern, ... Blood 134, 832, 2019 | 59 | 2019 |
| Phase II trial of pembrolizumab after high-dose cytarabine in relapsed/refractory acute myeloid leukemia JF Zeidner, BG Vincent, A Ivanova, D Moore, KP McKinnon, AD Wilkinson, ... Blood cancer discovery 2 (6), 616-629, 2021 | 58 | 2021 |
Ahmet ZehirVP, Bioinformatics在 natera.com 的电子邮件经过验证
